Opendata, web and dolomites


A breakthrough in Renal Cell Carcinoma: Personalized RCC-Test

Total Cost €


EC-Contrib. €






Project "RCC-TEST" data sheet

The following table provides information about the project.


Organization address
city: LABEGE
postcode: 31670
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme /SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-02-01   to  2016-07-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ICELLTIS FR (LABEGE) coordinator 50˙000.00


 Project objective

In oncology today, only 10 to 15% of patients respond strongly to therapeutic treatments. Metastatic renal cell cancer (mRCC) is no exception. It is one of the most treatment-resistant malignancies. 30% of patients are diagnosed with a metastatic disease. In such cases, the only solution is a radical surgical resection of the tumor, followed by the necessary therapies. About 80% of cases fail to respond to current therapeutic agents. New protocols with combined immuno- and targeted therapies have shown highly promising results. However, it is extremely difficult to interpret these results. Each patient is different and defining the appropriate set of therapies for mRCC has become increasingly complex. RCC-TEST is a new in vitro diagnostic tool, which will revolutionize the RCC post-surgical treatment. It will allow for rapid and cost-effective testing of a therapy’s effectiveness for each patient, before starting complex and expensive therapeutic protocols. Clinicians will be able to prescribe personalized treatments and to prolong patients’ lives, thereby reducing medical expenses. The new test is based on the ICELLTIS breakthrough 3D multicellular tumor spheroids, which are specific to RCC. For the first time, these spheroids are composed of the patient’s own tumor and immune cells, which are key determinants for the efficient in vitro investigation of responses and resistance of tumor cells to medical drugs. During Phase 1, ICELLTIS will scale-up RCC-TEST in order to prepare and be ready for further European clinical trials. A market study will be realized in order to investigate new international market opportunities and to challenge different commercial strategies. The main deliverable will be an updated business plan. ICELLTIS sees a huge business opportunity to further exploit their know-how in 3D (spheroid) tumor cell culture models. This feasibility study is an essential first step before the routine clinical practice and industrial production.

 Work performed, outcomes and results:  advancements report(s) 

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RCC-TEST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RCC-TEST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.;H2020-EU.2.3.1.)

BADGER (2017)

CalScreener® – an innovative device for Bacterial Analysis and Diagnostics through Growth and Energy-release in Real-time

Read More  

SDS-OmiProbe (2017)

Revolutionary opto-biological methodology for aggressive HER2 cancer

Read More  

ABC-S (2018)

Acoustic Blood Cells Sorter

Read More